Sign in or join now to see posts like this one and more.

Happy to share that I’ll be speaking at Research Revolution 2026!🎤 This event brings together the brightest minds in clinical research to share what’s working, what’s next, and how we can all move t...

The PROMISE Registry is a U.S.

This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.

ASCO 2026, DLL3-Directed T-Cell Engager, Tarlatamab, DLL3-Positive Metastatic Prostate Cancer, 89Zr-DFO-SC16, TIDAL study, STEAP1 and KLK2.

The future of high-risk prostate cancer treatment is taking shape — and the PCCTC is proud to be at the forefront!

The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced that investigators at Memorial Sloan Kettering Cancer Center (MSK) have enrolled the first patient in the TALENT study, a randomi...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Can the radioligand therapy 177Lu-PSMA-617 have an impact in older taxane-naïve men with mCRPC? Could we see the development of more combination therapies for patients with prostate cancer? Will emerg...

Sean McBride: Our AASUR Trial in High-Risk Prostate Cancer / cancer, Channing J Paller, Curtiland Deville, Dana Rathkopf, Daniel E Spratt, Han Xiao, Howard

The 2026 American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) was a landmark event for the Prostate Cancer Clinical Trials Consortium (PCCTC), and I could not be prouder of...

Just Published at JCO & POSTER NOW BEING PRESENTED 11:30-12:45pm ABSTRACT 162 Poster Bd E17 ( ⭐ Please Visit ⭐ ) American Society of Clinical Oncology (ASCO) #GU26 Trial Design and Objectives for P...

Just Published at JCO and out for #GU26 Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4 https://lnkd.in/dqfJFynp Here is Dr An...

/PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held, clinical-stage biotechnology company developing novel targeted therapies for cancers with...

At the 2026 ASCO Genitourinary Cancers Symposium, the international, multidisciplinary Prostate Cancer Working Group 4 will present its multiyear work to address unmet needs in the field of clinical r...

PCCTC Investigator Dr. Maha Hussain to Present BRCAAway Trial Results Showing Median Survival Exceeding 5 Years with Abiraterone Plus Olaparib at 2026 ASCO GU Symposium CHICAGO, IL – The Prostate...

The Prostate Cancer Clinical Trials Consortium today presented the Prostate Cancer Working Group 4 (PCWG4) clinical trials guidelines at the 2026 American Society for Clinical Oncology Genitourinary ...

Multiple Abstracts Highlight The PCCTC's Leadership in Advancing Prostate Cancer Clinical Trials and Treatment Standards The Prostate Cancer Clinical Trials Consortium (PCCTC) today announced that ...

SummaryThis Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the late...

/PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel targeted therapies for cancers with high...

The American Society of Clinical Oncology has produced its first continuously updated guidelines on systemic therapy for patients with metastatic castration-resistant prostate cancer. The new guidance...

Daniel J. George, MD, discusses the potential of radioligand therapies for patients with prostate cancer and the evolution of this treatment paradigm.

The PCCTC plans on hiring three summer interns next year to support Data Management , Data Science , and Clinical Operations . The 10-week internships are full-time, paid, 100% remote, and working ...

Leading clinical oncology stakeholders gathered in San Diego on 4 November for a half-day symposium hosted by Biocom California in partnership with the UC San Diego Moores Cancer Center, titled Innova...

Prostate Cancer and Prostatic Diseases - DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis

We’re thrilled to announce that our first site is officially activated for the KTX-2001 prostate cancer trial at #USAClinicalTrials in San Antonio, Texas! From regulatory packet submission to site ini...

Today we had the pleasure of welcoming representatives from the Prostate Cancer Clinical Trials Consortium (PCCTC) to the LACOG Office, together with Dr. André Poisl Fay, Brazil Investigator Lead for ...

AbstractPurpose:. Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3 (DL...

ASCO 2025 metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI) from A multinational real-world analysis of the IRONMAN registry.

Rana R. McKay, MD, FASCO, details the key efficacy and safety findings from the phase 2 COMRADE trial.

Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.

Welcome to ‘Cancer Clear and Simple,’ the podcast dedicated to simplifying cancer. Join us as we discuss the world of cancer, breaking down complex concepts for our listening audience. One of our goal...

Alan Bryce is joined by Michael Carducci to discuss consensus recommendations from the US Prostate Cancer Consensus Conference regarding PARP inhibitor testing and treatment strategies. Dr. Carducci e...

Panelists discuss how emerging trials like AMPLITUDE (PARP inhibitors for BRCA mutations), PSMA-ADDITION (radioligand therapy), and CAPITELLO (AKT inhibitors for PTEN deficiency) are moving the field ...